top of page
INNOVATIVE NASAL TREATMENTS IN CNS
We are targeting two different indications with great unmet patient needs
Epilepsy is responsible for high levels of suffering, affecting more than 50 million people worldwide, thus making it an important public health problem. In Europe, at least 5-6 million people have epilepsy, and 15 million people will have one seizure at some time in their lives. Epileptic seizures affect life conditions drastically and their treatment is of high unmet need. Until now, treatments are formulated as buccal solutions or tablets and suppositories, making their administration in a public area very uncomfortable for caregivers.
Anxiety can be found in various clinical settings in which the patient is feeling stressed or has anxiety (e.g. prior radiological diagnostic procedures, prior dentistry procedures, prior anesthetic induction, etc.). Due to its heritage in MRI research, Akroswiss is focusing primarily on the claustrophobia problematic encountered at MRI examinations. In Europe about 50 million MRI scans are performed annually and about 10-20% of patients are affected by anxiety.
Start: Disease areas
We are developing a new intranasal formulation for a minimal invasive drug administration with a unique 360° feature
FIRST IN CLASS "360° FUNCTIONALITY"
RAPID AND WELL-TOLERATED
NON INVASIVE ADMINISTRATION
SINGLE-USE AND HYGENIC
Akroswiss is pursuing European marketing authorization of its midazolam product portfolio and is currently compiling all documentation required for EMA submission.
WALTER P. HÖLZLE
Head of Business Development
bottom of page